Minsheng Securities Co., Ltd
About Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621)
Special verification report on the deposit and use of raised funds in 2021
Minsheng Securities Co., Ltd. (hereinafter referred to as “Minsheng securities” and “sponsor”) as the sponsor of Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) (hereinafter referred to as ” Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) ” and “company”) for initial public offering and listing on the science and innovation board, In accordance with the relevant provisions of the CSRC, such as the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies, the guidelines for the self-discipline supervision of listed companies on the science and Innovation Board of Shanghai Stock Exchange No. 1 – standardized operation, and the Listing Rules of shares on the science and Innovation Board of Shanghai Stock Exchange, Minsheng securities carefully verified the deposit and actual use of the raised funds in Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) 2021 (hereinafter referred to as “the reporting period”), and issued the following verification opinions:
1、 Basic information of raised funds
1. Amount of raised funds and arrival time of funds
According to the reply on Approving the registration of Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) initial public offering of shares (zjxk [2021] No. 1629) issued by China Securities Regulatory Commission, the application for registration of the company’s initial public offering of shares was approved, and the company was approved to issue 20000000 ordinary shares in RMB to the public. The par value of each share is 1 yuan, the issue price of each share is 26.89 yuan, and the total amount of funds raised in this issue is 537.8 million.00 yuan. After deducting the issuance expenses of 7061850755 yuan (relevant expenses are tax exclusive), the net amount of funds raised by the company’s public offering of new shares is 46718149245 yuan, Minsheng Securities Co., Ltd. remitted the balance of 49039800000 yuan after deducting the relevant underwriting recommendation fee (excluding tax) of 4740200000 yuan to the special account for raising funds of the company on June 16, 2021. Dahua Certified Public Accountants (special general partnership) verified the availability of funds for the public offering of new shares of the company, Zhyz No. [0001] issued on June 17, 2024. 2. Amount used and current balance of raised funds during the reporting period
The total amount of funds raised by the company is 53780000000 yuan, and the actual amount received after deducting the underwriting recommendation fee is 49039800000 yuan. The interest income from raised funds and cash management products received in 2021 was 157836400 yuan; In 2021, 10436015337 yuan of raised funds have been used (including some issuance expenses). The accumulated interest income of raised funds and cash management products received by the company is 157836400 yuan;
The accumulated used raised capital is 10436015337 yuan (including some issuance expenses). As of December 31, 2021, the balance of the special account for raised funds was 23011621063 yuan (including the accumulated interest income of raised funds and the interest income of cash management products). The specific use of the raised funds is as follows:
Project amount (yuan)
Receipt amount of special account for raised funds (1) 49039800000
As of December 31, 2021, the accumulated amount of raised funds used by the company is 1 (2) 10436015337
As of December 31, 2021, the amount of raised funds not used by the company is 38603784663 (3) = (1) – (2)
As of December 31, 2021, the amount of cash management products purchased by the company with raised funds is 1575000000 (4)
As of December 31, 2021, the company used idle raised funds to temporarily supplement the amount of 0.00 working capital (5)
As of December 31, 2021, the amount of interest income from the company’s special account for raised funds and cash management 157836400 products (6)
Balance of funds raised by the company (as of December 31, 2026) = (230.63) – (as of December 31, 2026)
Note 1: the accumulated amount of raised funds used includes part of the issuance expenses.
2、 Management of raised funds
1. Management of raised funds
In order to standardize the management and use of the raised funds and protect the rights and interests of investors, the company has formulated the measures for the management of the raised funds of the company (hereinafter referred to as the management measures) in accordance with the provisions of the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of the raised funds of listed companies and in combination with the actual situation of the company Specific and clear provisions have been made on the use and supervision of the use, and the funds are stored, used and managed in accordance with the provisions of the management system.
In June 2021, Bank Of Hangzhou Co.Ltd(600926) Beijing Beijing Centergate Technologies (Holding) Co.Ltd(000931) sub branch, China Merchants Bank Co.Ltd(600036) Beijing Dayun village sub branch, Industrial Bank Co.Ltd(601166) Beijing Branch Changping sub branch, Bank Of Ningbo Co.Ltd(002142) Beijing Branch, Minsheng Securities Co., Ltd., the company and relevant subsidiaries signed a tripartite supervision agreement on the storage of raised funds. There is no significant difference in the model regulatory agreement. The company stores, uses and manages the raised funds in strict accordance with the provisions of the regulatory agreement. The details of account opening are as follows:
Bank account name deposit bank name account number corresponding to raised investment construction content
Special preparation R & D platform project
Beijing Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) Bank Of Hangzhou Co.Ltd(600926) Co., Ltd. has a drug innovation and R & D platform project
Pharmaceutical Research Co., Ltd. Beijing Zhongguan 1101040160001319119 clinical trial service platform construction project Co., Ltd. village sub branch innovative drug PK / PD research platform project
Beijing Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) Bank Of Hangzhou Co.Ltd(600926) Co., Ltd. has 11010401600001319101 special preparation R & D platform project
Pharmaceutical Research Co., Ltd. Beijing Zhongguan
Limited company Village sub branch
Special preparation R & D platform project
Beijing Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) China Merchants Bank Co.Ltd(600036) Co., Ltd. has a drug innovation and R & D platform project
Pharmaceutical Research Co., Ltd. Beijing Dayun 110943202110302 clinical trial service platform construction project Co., Ltd. village sub branch innovative drug PK / PD research platform project
Special preparation R & D platform project
Beijing Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) Industrial Bank Co.Ltd(601166) Co., Ltd. has a drug innovation and R & D platform project
Pharmaceutical Research Co., Ltd. Beijing Branch 3213 Jinneng Holding Shanxi Coal Industry Co.Ltd(601001) 00340407 clinical trial service platform construction project Co., Ltd. Changping sub branch innovative drug PK / PD research platform project
Special preparation R & D platform project
Beijing Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) Bank Of Ningbo Co.Ltd(002142) Co., Ltd. has a drug innovation and R & D platform project
Pharmaceutical Research Co., Ltd. Beijing Branch 77170122 China Vanke Co.Ltd(000002) 518 clinical trial service platform construction project Co., Ltd. innovative drug PK / PD research platform project
Beijing Sunshine Demi Industrial Bank Co.Ltd(601166) Co., Ltd. has innovative drug PK / PD research platform item Pharmaceutical Technology Co., Ltd. Beijing Changping 3213 Liuzhou Iron&Steel Co.Ltd(601003) 40516 project
Company sub branch
Beijing novo Mart Bank Of Ningbo Co.Ltd(002142) Co., Ltd
Medical Technology Co., Ltd. Beijing Changping 77170122 China Vanke Co.Ltd(000002) 671 clinical trial service platform construction project company sub branch business department
Chengdu novo Shengtai China Merchants Bank Co.Ltd(600036) Co., Ltd
Beijing Dayun 128908996810401 pharmaceutical innovation research and development platform project of Biotechnology Co., Ltd
Company Village sub branch
On August 19, 2021, the company held the 12th meeting of the first board of directors, deliberated and approved the proposal on increasing the implementation subject and changing the implementation location of some raised investment projects, and agreed to add wholly-owned subsidiaries of the company’s special preparation R & D platform project: Beijing Hongsheng pharmaceutical science and technology Co., Ltd., Beijing Nuohe Hengguang Pharmaceutical Technology Co., Ltd Chengdu Nuohe Shengxin Testing Technology Co., Ltd., Chengdu Nuohe Shenghong biopharmaceutical Co., Ltd. and its holding subsidiary Jiangsu Nuohe bituo new drug R & D Co., Ltd. are the implementation subjects of the raised investment project.
Shanghai paisixin Biomedical Technology Co., Ltd., a new holding subsidiary of the company’s innovative drug PK / PD research platform project, is the implementation subject of the raised investment project. Nanjing Xianning Pharmaceutical Technology Co., Ltd., a new holding subsidiary of the company’s clinical trial service platform construction project, is the implementation subject of the raised investment project. In September 2021, more than new implementing entities opened a special account for raised funds in Bank Of Hangzhou Co.Ltd(600926) Beijing Beijing Centergate Technologies (Holding) Co.Ltd(000931) sub branch, and signed a tripartite supervision agreement for raised funds with the sponsor and the supervision Bank of the special account for raised funds. There is no significant difference between the contents of the agreement and the tripartite supervision agreement (model) on the storage of special accounts for raised funds formulated by Shanghai Stock Exchange. The details of account opening are as follows:
Bank account name deposit bank name account number corresponding to raised investment construction content
Beijing Hongsheng Pharmaceutical Bank Of Hangzhou Co.Ltd(600926) Co., Ltd
Beijing Zhongguan 1101040160000135980 special preparation R & D platform project of Technology Co., Ltd
Village sub branch
Jiangsu novo Billiton Bank Of Hangzhou Co.Ltd(600926) Co., Ltd
Beijing Zhongguan 11010401 Lucky Film Company Limited(600135) 956 special preparation R & D platform project of new drug R & D Co., Ltd
Company Village sub branch
Nanjing Xianning Pharmaceutical Bank Of Hangzhou Co.Ltd(600926) Co., Ltd
Beijing Zhongguan 1101040160000135873 clinical trial service platform construction project village sub branch of Technology Co., Ltd
Beijing novo Hengguang Bank Of Hangzhou Co.Ltd(600926) Co., Ltd
Beijing Zhongguan 11010401 Lucky Film Company Limited(600135) 8828 special preparation R & D platform project of Pharmaceutical Technology Co., Ltd
Company Village sub branch
Shanghai paisiweixin Bank Of Hangzhou Co.Ltd(600926) Co., Ltd
Biomedical Technology Co., Ltd. Beijing Zhongguan 11010401600001361343 innovative drug PK / PD research platform project Co., Ltd. village sub branch
Chengdu novo Shengxin Bank Of Hangzhou Co.Ltd(600926) Co., Ltd
Beijing Zhongguan 11010401600001361319 special preparation R & D platform project of Testing Technology Co., Ltd
Company Village sub branch
Chengdu novo Shenghong Bank Of Hangzhou Co.Ltd(600926) Co., Ltd
Beijing Zhongguan 11010401600001361368 special preparation R & D platform project of biopharmaceutical Co., Ltd
Company Village sub branch
2. Storage of raised funds in special account
As of December 31, 2021, the specific deposit of raised funds is as follows:
Bank account name deposit bank name account number amount
(RMB)
Beijing Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) Bank Of Hangzhou Co.Ltd(600926) Co., Ltd
Pharmaceutical Research Co., Ltd. Beijing Beijing Centergate Technologies (Holding) Co.Ltd(000931) branch 11010401600001319119
